177 related articles for article (PubMed ID: 26187654)
1. PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab.
Salahudeen AA; Gupta A; Jones JC; Cowan RW; Vusirikala M; Kwong C; Naina HV
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):e137-40. PubMed ID: 26187654
[No Abstract] [Full Text] [Related]
2. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
[TBL] [Abstract][Full Text] [Related]
3. Symptomatic Hypercalcemia in a Patient with B-cell Chronic Lymphocytic Leukemia - A Case Report and Review of the Literature.
Koutroumpakis E; Lobe M; McCarthy L; Mehdi S
In Vivo; 2016 09-10; 30(5):691-4. PubMed ID: 27566092
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody.
Sato K; Onuma E; Yocum RC; Ogata E
Semin Oncol; 2003 Oct; 30(5 Suppl 16):167-73. PubMed ID: 14613038
[TBL] [Abstract][Full Text] [Related]
5. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
Harsch IA; Konturek PC
Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
[TBL] [Abstract][Full Text] [Related]
6. Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.
Teng J; Abell S; Hicks RJ; Hofman MS; Sachithanandan N; McKelvie P; MacIsaac RJ
Clin Endocrinol (Oxf); 2014 Dec; 81(6):940-2. PubMed ID: 24890549
[No Abstract] [Full Text] [Related]
7. Incidence of humoral hypercalcemia of malignancy among hypercalcemic patients with cancer.
Szymanski JJ; Otrock ZK; Patel KK; Scott MG
Clin Chim Acta; 2016 Jan; 453():190-3. PubMed ID: 26706788
[TBL] [Abstract][Full Text] [Related]
8. A rare case of chronic lymphocytic leukemia with hypercalcemia induced by elevated parathyroid hormone-related peptides.
Kampfenkel T; Baraniskin A; Teschendorf C; Schmiegel W; Massenkeil G
Acta Haematol; 2010; 124(1):57-60. PubMed ID: 20616540
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone-related protein in tumor tissues obtained from patients with humoral hypercalcemia of malignancy.
Tsuchihashi T; Yamaguchi K; Miyake Y; Otsubo K; Nagasaki K; Honda S; Akiyama Y; Maeda Y; Koike M; Alper O
J Natl Cancer Inst; 1990 Jan; 82(1):40-4. PubMed ID: 2293655
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate-responsive calcitriol-mediated hypercalcemia in a 5-year-old case with squamous cell carcinoma on the background of xeroderma pigmentosum.
Colak U; Mutlu GY; Sozmen BO; Yucel EB; Kayserili H; Hatun S
J Pediatr Endocrinol Metab; 2019 Dec; 32(12):1403-1406. PubMed ID: 31782950
[TBL] [Abstract][Full Text] [Related]
11. Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting neuroendocrine tumors. Report of six cases.
Milanesi A; Yu R; Wolin EM
Pancreatology; 2013; 13(3):324-6. PubMed ID: 23719609
[TBL] [Abstract][Full Text] [Related]
12. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
[No Abstract] [Full Text] [Related]
13. [Treatment of malignancy associated hypercalcemia].
Tai N; Inoue D
Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a transplantable tumor line (IP) derived from rat pulmonary carcinoma, developing humoral hypercalcemia of malignancy in IP-bearing rats.
Nakanishi M; Yamate J; Nakatsuji S; Ide M; Sawamoto O; Kuwamura M; Kotani T; Sakuma S
Virchows Arch; 2002 Feb; 440(2):195-204. PubMed ID: 11964051
[TBL] [Abstract][Full Text] [Related]
15. Morphological characteristics of tumors with humoral hypercalcemia of malignancy: functional morphology of PTHrP.
Turzynski A; Baumgart S; Bauch B; Dietel M
Recent Results Cancer Res; 1994; 137():76-97. PubMed ID: 7878296
[No Abstract] [Full Text] [Related]
16. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid Hormone-Related Peptide-Linked Hypercalcemia in a Melanoma Patient Treated With Ipilimumab: Hormone Source and Clinical and Metabolic Correlates.
Mills TA; Orloff M; Domingo-Vidal M; Cotzia P; Birbe RC; Draganova-Tacheva R; Martinez Cantarin MP; Tuluc M; Martinez-Outschoorn U
Semin Oncol; 2015 Dec; 42(6):909-14. PubMed ID: 26615135
[TBL] [Abstract][Full Text] [Related]
18. Malignant hypercalcemia in vulvar cancer.
Bilenchi R; Poggiali S; Pisani C; Santopietro R; Miracco C; Vatti R; Lucani B; Andreassi A; Gonnelli S
Minerva Ginecol; 2005 Oct; 57(5):569-74. PubMed ID: 16205603
[TBL] [Abstract][Full Text] [Related]
19. A Case of Hypercalcemia from PTHrP-Producing Fibromyxoid Sarcoma Responsive to Glucocorticoid Therapy.
Niu I; Hsiao EC; Wustrack R; Wysolmerski JJ; Dann P; Masharani U
Calcif Tissue Int; 2023 Aug; 113(2):246-253. PubMed ID: 37358786
[TBL] [Abstract][Full Text] [Related]
20. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
